Allison Nicklin, Goodwin Procter LLP, Partner, Life Sciences

Allison P. Nicklin

Partner
Allison P. Nicklin
Philadelphia
+1 316 617 3338

Allison Nicklin is a partner in the Life Sciences group at Goodwin. Allison focuses her practice on advising public and private pharmaceutical, biochemical, and medical device companies in mergers, acquisitions, licensing and collaboration transactions, and other strategic transactions. She also represents life sciences companies in private placements, venture capital, and other capital-raising transactions and advises clients on a wide variety of matters, including pre-incorporation/formation structuring, corporate governance, and strategic and commercial matters.

Prior to joining Goodwin in 2023, Allison was a partner at Troutman Pepper Hamilton Sanders LLP.

Representative Matters

Allison’s Representative Matters include the following:

  • Represented a global pharmaceutical company in the license of a late-stage antibiotic for the treatment of complicated urinary tract infections; transaction includes up to $600 million in milestone payments*
  • Represented and pharmaceutical company in connection with its license and collaboration with a neuroscience-focused, biopharmaceutical company in order to develop first-in-class treatments for epilepsy*
  • Represented a biotechnology company in a licensing and collaboration agreement for two protein therapy platforms with a leader in RNA-targeting therapeutics*
  • Represented biotechnology and pharmaceutical companies in connection with various research, development and collaboration agreements, license agreements, strategic funding transactions, and supply, commercialization and co-promote agreements*
  • Represented a global pharmaceutical company in connection with multiple companion diagnostic development, manufacture and supply transactions*

* Denotes experience prior to joining Goodwin

  • Represented a cell and gene therapy manufacturer in connection with its $350 million equity financing*
  • Represented a regenerative medicine biotechnology company in connection with its $40 million preferred stock financing*
  • Represented a cell therapy biotechnology company in connection with its restructuring and $160 million preferred stock financing*
  • Represented numerous biotechnology, health care, and specialty pharmaceutical companies in connection with formation, seed, and venture financing, bridge notes and other debt financings and general corporate matters*
  • Represented multiple biotechnology startups in connection with sponsored research agreements, option and licensing agreements, and other collaborations with universities and academic institutions*

*Denotes experience prior to joining Goodwin

  • Represented a private equity-backed manufacturer of biomaterial coatings for medical devices in its strategic acquisition by a private equity fund*
  • Represented a global pharmaceutical company focused on allergy diagnosis and treatment in the sale of its US veterinary business to a Swedish companion-animal allergy testing and treatment company*
  • Represented a specialty pharmaceutical company focused on therapeutics for acute care settings in its spin-off from a public contract manufacturing organization and listing on the Nasdaq Capital Market*
  • Represented a publicly traded international generic pharmaceutical company in the potential acquisition of a branded pharmaceutical company*
  • Represented a global laboratory testing company in the acquisition of an analytical laboratory focused on environmental and agricultural testing*

* Denotes experience prior to joining Goodwin

Credentials

Education

JD2014

Villanova University Charles Widger School of Law

(cum laude, associate editor and staff writer, Environmental Law Journal)

BA2009

Southern Methodist University

Admissions

Bars

  • Pennsylvania
  • New Jersey

Professional Experience

Allison was an Associate Counsel with Versa Capital Management, LLC from 2014-2018

Recognition & Awards

Listed in Best Lawyers in America: Ones to watch: Health Care Law (2022-2023)